Further evidence that IGF-1 can encourage the development of CRC in T2DM patients was found to be provided by the association between each unit increase in IGF-1R and an approximately 0.96-fold increase in the probability of developing CRC. This evidence concerns the gene IGF1 and colorectal carcinoma.